Nadubinszky Gábor, Székács Béla, Rihmer Zoltán
Szent Imre Egyetemi Oktatokorhaz, Pszichiatriai Osztaly, Budapest, Hungary, E-mail:
Psychiatr Hung. 2022;37(1):5-12.
Initially, it had been assumed that in cases of SARS-CoV-2 infection comorbidity with psychiatric disorders worsens clinical outcomes. This was attributed to patients' poor overall health conditions, concomitant illnesses and unhealthy lifestyles. However, only schizophrenia is in a statistically significant correlation with very serious conditions leading to death, possibly as a result of underlying immune dysfunctions. Clozapine (an antipsychotic used in therapy of treatment resistant schizophrenia) seems to decrease the likelihood of recovery in COVID-19 patients, however admi nistration of antidepressant medications appears to increase it. It has also been justified that among these antidepressant drugs, fluvoxamin shows to have an effect in inhibiting cytokine storms and reducing the severity of the COVID-19 infection. Most recent data suggest that the well-known antiviral effect of lithium is also present in patients with COVID-19 infection.
最初，人们认为在感染新冠病毒的病例中，合并精神疾病会使临床结果恶化。这归因于患者总体健康状况不佳、合并疾病和不健康的生活方式。然而，只有精神分裂症与导致死亡的非常严重的情况存在统计学上的显著相关性，这可能是潜在免疫功能障碍的结果。氯氮平（一种用于治疗难治性精神分裂症的抗精神病药物）似乎会降低新冠患者康复的可能性，然而使用抗抑郁药物似乎会增加康复的可能性。也有理由认为，在这些抗抑郁药物中，氟伏沙明显示出有抑制细胞因子风暴和降低新冠感染严重程度的作用。最新数据表明，锂的著名抗病毒作用在新冠感染患者中也存在。
